Author

U. Chukwueke

h-index 24 View on Semantic Scholar

We have 3 of 144 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Prognostic Significance of Contrast Enhancement in Newly Diagnosed Grade 2 IDH-mutant Glioma.

BACKGROUND Contrast enhancement is generally considered an adverse prognostic feature in adult glioma. However, its significance in newly diagnosed grade 2 IDH-mutant glioma remains uncertain, with important implications for use of the mutant IDH inhibitor vorasidenib. We evaluated survival outcomes associated with pre...

Vihang Nakhate, Aleksandra B. Lasica, Loai Aker et al. · Neuro-Oncology · 0 citations

Open access Sep 2026

Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial

We conducted a randomized surgical window-of-opportunity trial (NCT04606316) in recurrent, resectable glioblastoma. Between 2021 and 2024, 71 patients were screened, and 63 were randomized (intention-to-treat [ITT] population), and 58 received study treatment. Patients received pre-surgical immune checkpoint blockade (...

Lu Sun, Lauren Markus, Julio C. Sanchez et al. · Nature Communications · 0 citations

Open access Jul 2026

Germline determinants of risk and molecular subtype in young-onset lung cancer

A complex germline architecture underlying susceptibility and molecular subtype in young-onset lung cancer is delineated, consistent with additive risk from rare and common variants.

J. LoPiccolo, Ryan L. Collins, Noah Fields et al. · medRxiv · 0 citations